VOR
Vor Biopharma Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Neutral
-3/100
Last price
18.31
▼ 0.27 (1.45%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
18.58
Day high
18.87
Day low
17.97
Volume
472.77K
Market cap
$1.08B
P/E (TTM)
0.10
52W range
6.50 – 34.63
Trailing performance
Returnvs SPY
1W
-0.11%
-2.1%
1M
-26.91%
-28.1%
3M
-9.85%
-14.4%
6M
+8.66%
-9.5%
YTD
+39.98%
+25.7%
1Y
-51.12%
-67.5%
3Y
-56.82%
-139.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on VOR open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+1.20M
Net buying
Buy transactions
3
2.10M shares
Sell transactions
3
903.35K shares
Net transactions
+6
Buys less sells
Sell : buy shares
0.4 : 1
Mixed
Insider-held shares
5.48M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Oct 2, 26 | RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security |
CONVERSION | 500 | $6.40K | Indirect |
| Aug 24, 26 | RA CAPITAL HEALTHCARE FUND,L.P. Beneficial Owner of more than 10% of a Class of Security |
CONVERSION | 1.50K | $5.60K | Indirect |
| Jul 16, 26 | RA CAPITAL HEALTHCARE FUND,L.P. Beneficial Owner of more than 10% of a Class of Security |
CONVERSION | 2.10M | $4.20K | Indirect |
| Jul 16, 26 | RA CAPITAL HEALTHCARE FUND,L.P. Beneficial Owner of more than 10% of a Class of Security |
SELL | 213 | $4.21K | Indirect |
| Apr 22, 26 | RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security |
SELL | 165.15K | $2.60M | Indirect |
| Apr 15, 26 | RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security |
SELL | 737.99K | $11.88M | Indirect |
| Apr 6, 26 | RA CAPITAL MANAGEMENT, L.P. Director and Beneficial Owner of more than 10% of a Class of Security |
SELL | 849.26K | $14.52M | Indirect |
| Oct 30, 25 | RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security |
SELL | 400.41K | $10.37M | Indirect |
| Oct 27, 25 | RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security |
SELL | 221.17K | $6.20M | Indirect |
| Oct 21, 25 | RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security |
SELL | 117.05K | $3.43M | Indirect |
| Oct 21, 25 | REPROGRAMMED INTERCHANGE LLC Beneficial Owner of more than 10% of a Class of Security |
SELL | 37.53K | $1.13M | Direct |
| Oct 17, 25 | RA CAPITAL HEALTHCARE FUND,L.P. Director and Beneficial Owner of more than 10% of a Class of Security |
SELL | 464.02K | $13.71M | Indirect |
| Oct 16, 25 | REPROGRAMMED INTERCHANGE LLC Beneficial Owner of more than 10% of a Class of Security |
SELL | 73.68K | $2.35M | Direct |
| Oct 14, 25 | REPROGRAMMED INTERCHANGE LLC Beneficial Owner of more than 10% of a Class of Security |
SELL | 96.66K | $3.00M | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ANG ROBERT M.D. |
Chief Executive Officer | 921.74K | Stock Award(Grant) |
ATTAR EYAL C |
Officer | 126.63K | Sale |
CHAKRABORTY TIRTHA |
Officer | 221.27K | Stock Award(Grant) |
CHOI HAN WOOK |
Chief Financial Officer | 52.50K | Stock Award(Grant) |
MAHATME SANDESH |
Chief Financial Officer | 13.88M | Stock Award(Grant) |
RA CAPITAL HEALTHCARE FUND,L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Conversion of Exercise of derivative security |
RA CAPITAL MANAGEMENT, L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Conversion of Exercise of derivative security |
REPROGRAMMED INTERCHANGE LLC |
Beneficial Owner of more than 10% of a Class of Security | 1.17M | Sale |
ZURAW QING CHE |
Officer | 937.08K | Stock Award(Grant) |
Fundamentals
Market cap$1.08B
Enterprise value$620.01M
Revenue (TTM)—
Gross profit—
EBITDA$-117.28M
Net income$627.78M
EPS (TTM)$180.18
Free cash flow$-79.50M
Total cash$466.13M
Total debt$2.88M
Book value / share$-3.68
Shares outstanding59.16M
Float37.23M
Short % of float15.72%
Dividend yield0.00%
Beta (5Y)1.78
Valuation & profitability ratios
Trailing P/E0.10
Forward P/E-4.80
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA-5.29
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity—
Return on assets-21.37%
Debt / equity—
Current ratio19.15
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $321.53M | $93.31M | $94.31M | $64.55M | +244.6% |
| Selling, general & admin | $50.11M | $27.88M | $31.72M | $28.87M | +79.8% |
| Total operating expense | $371.64M | $121.19M | $126.04M | $93.42M | +206.7% |
| Operating income | -$371.64M | -$121.19M | -$126.04M | -$93.42M | -206.7% |
| Net interest income | $5.87M | $4.27M | $8.17M | $1.32M | +37.4% |
| Pre-tax income | -$695.98M | -$116.91M | -$117.86M | -$92.09M | -495.3% |
| Net income | -$695.98M | -$116.91M | -$117.86M | -$92.09M | -495.3% |
| Net income to common | -$695.98M | -$116.91M | -$117.86M | -$92.09M | -495.3% |
| Basic EPS | -70.50 | -34.03 | -35.00 | -46.60 | -107.2% |
| Diluted EPS | -70.50 | -34.03 | -35.00 | -46.60 | -107.2% |
| EBIT | -$371.64M | -$121.19M | -$126.04M | -$93.42M | -206.7% |
| EBITDA | -$368.75M | -$117.66M | -$122.54M | -$90.89M | -213.4% |
| Basic shares | 9.87M | 3.44M | 3.36M | 1.98M | +187.3% |
| Diluted shares | 9.87M | 3.44M | 3.36M | 1.98M | +187.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $396.49M | $81.95M | $31.36M | $57.71M | +383.8% |
| Cash & short-term investments | $455.21M | $91.93M | $137.18M | $230.25M | +395.2% |
| Total current assets | $458.11M | $96.51M | $140.80M | $236.95M | +374.7% |
| Property, plant & equipment | $3.47M | $41.59M | $50.10M | $57.08M | -91.7% |
| Total assets | $464.13M | $142.89M | $198.13M | $299.37M | +224.8% |
| Total current liabilities | $25.17M | $18.61M | $15.57M | $13.12M | +35.2% |
| Total debt | $3.00M | $31.83M | $35.66M | $38.91M | -90.6% |
| Total liabilities | $628.44M | $46.23M | $47.40M | $48.76M | +1,259.5% |
| Retained earnings | -$1.15B | -$456.99M | -$340.08M | -$222.22M | -152.3% |
| Shareholder equity | -$164.31M | $96.66M | $150.72M | $250.61M | -270.0% |
| Working capital | $432.93M | $77.89M | $125.23M | $223.83M | +455.8% |
| Net tangible assets | -$164.31M | $96.66M | $150.72M | $250.61M | -270.0% |
| Shares issued | 38.72M | 6.24M | 3.39M | 3.30M | +520.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$695.98M | -$116.91M | -$117.86M | -$92.09M | -495.3% |
| Depreciation & amortisation | $2.89M | $3.53M | $3.49M | $2.52M | -18.2% |
| Stock-based compensation | $18.91M | $9.85M | $13.36M | $10.70M | +92.1% |
| Change in working capital | $10.21M | $5.00K | $650.00K | -$9.84M | +204,060.0% |
| Operating cash flow | -$142.71M | -$99.66M | -$100.29M | -$85.14M | -43.2% |
| Capital expenditure | -$941.00K | -$229.00K | -$1.07M | -$8.46M | -310.9% |
| Investing cash flow | -$48.80M | $96.86M | $71.01M | -$94.09M | -150.4% |
| Financing cash flow | $503.81M | $53.39M | $2.94M | $117.14M | +843.6% |
| Free cash flow | -$143.65M | -$99.89M | -$101.36M | -$93.61M | -43.8% |
| End cash position | $396.65M | $84.36M | $33.77M | $60.12M | +370.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $25.92M | $17.59M | $19.19M | $14.14M | $261.50M | — | +47.3% |
| Selling, general & admin | $21.93M | $17.57M | $16.77M | $13.96M | $12.79M | — | +24.9% |
| Total operating expense | $47.85M | $35.16M | $35.96M | $28.11M | $274.28M | — | +36.1% |
| Operating income | -$47.85M | -$35.16M | -$35.96M | -$28.11M | -$274.28M | — | -36.1% |
| Net interest income | $4.34M | $3.94M | $2.79M | $1.73M | $537.00K | — | +10.4% |
| Pre-tax income | -$62.81M | -$219.59M | $1.72B | -$812.68M | -$1.57B | — | +71.4% |
| Net income | -$62.81M | -$219.59M | $1.72B | -$812.68M | -$1.57B | — | +71.4% |
| Net income to common | -$62.81M | -$219.59M | $1.72B | -$812.68M | -$1.57B | — | +71.4% |
| Basic EPS | -1.16 | -5.11 | — | -121.63 | -251.24 | -5.21 | +77.3% |
| Diluted EPS | -1.16 | -5.11 | — | -121.63 | -251.24 | -5.21 | +77.3% |
| EBIT | -$47.85M | -$35.16M | -$35.96M | -$28.11M | -$274.28M | — | -36.1% |
| EBITDA | -$47.82M | -$35.13M | -$35.94M | -$28.11M | -$272.25M | — | -36.1% |
| Basic shares | 54.30M | 43.01M | — | 6.68M | 6.26M | 6.24M | +26.3% |
| Diluted shares | 54.30M | 43.01M | — | 6.68M | 6.26M | 6.24M | +26.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $107.86M | $169.87M | $396.49M | $160.46M | $190.57M | -36.5% |
| Cash & short-term investments | $466.13M | $491.52M | $455.21M | $170.46M | $200.56M | -5.2% |
| Total current assets | $475.11M | $500.78M | $458.11M | $172.49M | $204.93M | -5.1% |
| Property, plant & equipment | $3.37M | $3.39M | $3.47M | $3.31M | $24.00K | -0.8% |
| Total assets | $481.05M | $506.75M | $464.13M | $176.24M | $205.37M | -5.1% |
| Total current liabilities | $24.81M | $16.08M | $25.17M | $18.84M | $58.77M | +54.3% |
| Total debt | $2.88M | $2.94M | $3.00M | $3.06M | $0 | -2.1% |
| Total liabilities | $681.25M | $657.17M | $628.44M | $2.40B | $1.71B | +3.7% |
| Retained earnings | -$1.44B | -$1.37B | -$1.15B | -$2.88B | -$2.06B | -4.6% |
| Shareholder equity | -$200.20M | -$150.42M | -$164.31M | -$2.23B | -$1.51B | -33.1% |
| Working capital | $450.29M | $484.70M | $432.93M | $153.65M | $146.15M | -7.1% |
| Net tangible assets | -$200.20M | -$150.42M | -$164.31M | -$2.23B | -$1.51B | -33.1% |
| Shares issued | 54.46M | 54.19M | 38.72M | 9.03M | 6.28M | +0.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$62.81M | -$219.59M | $1.72B | -$812.68M | -$1.57B | +71.4% |
| Depreciation & amortisation | $36.00K | $28.00K | $23.00K | $2.00K | $2.04M | +28.6% |
| Stock-based compensation | $9.40M | $8.87M | $7.11M | $8.03M | $1.84M | +6.0% |
| Change in working capital | $9.01M | -$15.54M | $3.16M | $5.06M | $4.63M | +158.0% |
| Operating cash flow | -$25.38M | -$38.25M | -$22.80M | -$53.66M | -$35.18M | +33.6% |
| Capital expenditure | -$120.00K | -$48.00K | -$314.00K | -$244.00K | -$152.00K | -150.0% |
| Investing cash flow | -$36.53M | -$263.24M | -$48.97M | -$244.00K | $646.00K | +86.1% |
| Financing cash flow | -$106.00K | $74.87M | $307.80M | $21.55M | $175.06M | -100.1% |
| Free cash flow | -$25.50M | -$38.29M | -$23.11M | -$53.91M | -$35.34M | +33.4% |
| End cash position | $108.02M | $170.04M | $396.65M | $160.63M | $192.99M | -36.5% |
Options analytics
Put / call volume
3.68
Put-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
17.50
-4.4% from spot
ATM implied vol
12.5%
Nearest strike to spot
Skew (10% OTM)
-6.2%
Calls bid over puts
Call volume
31
Contracts, this expiry
Put volume
114
Contracts, this expiry
Heaviest call OI
20.00
0 contracts
Heaviest put OI
17.50
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.70 | -0.80 | -14.0% |
| Mar 2026 | -0.78 | -0.73 | +7.2% |
| Dec 2025 | -1.19 | 307.53 | +25,920.3% |
| Sep 2025 | -4.10 | -121.63 | -2,866.6% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.72 | 1 | $0 | 0.0% |
| Next quarter | -0.77 | 1 | $0 | 0.0% |
| Current year | -6.53 | 1 | $0 | 0.0% |
| Next year | -3.82 | 4 | $0 | 0.0% |
Analyst targets & ownership
Mean target$39.00
High target$50.00
Low target$27.00
Implied upside113.00%
Analyst count8
ConsensusSTRONG BUY
Strong buy / Buy1 / 7
Hold1
Sell / Strong sell0 / 0
Held by insiders9.26%
Held by institutions86.84%
Institutions holding155
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
18.57
-1.39% from price
SMA 20
20.40
-10.27% from price
SMA 50
21.93
-16.52% from price
SMA 100
19.09
-4.11% from price
SMA 200
16.80
+9.01% from price
EMA 12
19.25
-4.88% from price
EMA 26
20.39
-10.18% from price
EMA 50
20.63
-11.25% from price
RSI (14)
35.8
Neutral
MACD (12,26,9)
-1.14
Hist -0.22
ATR (14)
1.31
7.17% of price
Realised vol 30D
64.1%
Annualised
Bollinger upper
24.19
20, 2σ
Bollinger lower
16.62
20, 2σ
50 / 200 cross
Golden
21.93 vs 16.80
Trend bias
Above 200
+9.01%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.66
More volatile than market
Correlation to SPY
0.21
Largely independent
Realised vol 30D
64.1%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-80.8%
Peak to trough
Max drawdown 5Y
-99.2%
Peak to trough
ATR 14
1.31
7.17% of price
Beta (reported)
1.78
5Y monthly, from filing
Short interest
Shares short
7.90M
Prior 7.35M
Change vs prior
+7.5%
Shorts adding
% of float
15.72%
Elevated
% of shares out
13.36%
Against total outstanding
Days to cover
10.8
Crowded exit
Float
37.23M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 12, 26 | Wedbush | MAINTAINED | Neutral | Neutral |
| May 18, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 14, 26 | Wedbush | MAINTAINED | Neutral | Neutral |
| Apr 15, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 31, 26 | Wedbush | MAINTAINED | Neutral | Neutral |
| Mar 30, 26 | Jefferies | INITIATED | — | Buy |
| Mar 19, 26 | Wells Fargo | INITIATED | — | Overweight |
| Jan 9, 26 | Citigroup | INITIATED | — | Buy |
| Dec 19, 25 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Dec 17, 25 | TD Cowen | INITIATED | — | Buy |
| Dec 9, 25 | JP Morgan | INITIATED | — | Overweight |
| Nov 14, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:20
Split dateSep 19, 2025
SEC filings
Offering Registrations
S-3ASR · 2026-09-04
Periodic Financial Reports
10-Q · 2026-08-11
Corporate Changes & Voting Matters
8-K · 2026-07-07
Corporate Changes & Voting Matters
8-K · 2026-06-12
Corporate Changes & Voting Matters
8-K · 2026-06-08
Periodic Financial Reports
10-Q · 2026-05-13
A correspondence can be sent as a document with another submission type or can be sent as a separate submission
CORRESP · 2026-05-04
Offering Registrations
S-3 · 2026-04-27
Headlines
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 2d ago
Durable MG Responses From Telitacicept Could Be A Game Changer For Vor Biopharma (VOR)
Simply Wall St. · 3d ago
Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
GlobeNewswire · 8d ago
Sjögren's Syndrome Market to Witness Sustained Growth During the Forecast Period (2026-2036) Due to the Development of Targeted Immunotherapies, FcRn Inhibitors, TYK2 Inhibitors, and Cell Therapies | DelveInsight
PR Newswire · 21d ago
Vor Biopharma Completes Enrollment in Phase 3 Trial of Investigational Drug for Generalized Myasthenia Gravis
MT Newswires · 29d ago
Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis
GlobeNewswire · 29d ago
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 33d ago
Vor Bio To Participate in Upcoming September Conferences
GlobeNewswire · 36d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.